As filed with the Securities and Exchange Commission on May 9, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Verrica Pharmaceuticals Inc.
(Exact name of Registrant as specified in its charter)
| | |
Delaware | | 46-3137900 |
(State or other jurisdiction of Incorporation or organization) | | (I.R.S. Employer Identification No.) |
44 West Gay Street, Suite 400
West Chester, PA 19380
(Address of principal executive offices) (Zip code)
2018 Equity Incentive Plan
(Full title of the plan)
Ted White
President and Chief Executive Officer
Verrica Pharmaceuticals Inc.
44 West Gay Street, Suite 400
West Chester, PA 19380
(484) 453-3300
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
Darren DeStefano
Mark Ballantyne
Cooley LLP
11951 Freedom Drive
Reston, VA 20190-5640
(703) 456-8000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | |
Large accelerated filer | | ☐ | | Accelerated filer | | ☐ |
| | | |
Non-accelerated filer | | ☒ | | Smaller reporting company | | ☒ |
| | | |
| | | | Emerging growth company | | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒